<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02851758</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-P00014558</org_study_id>
    <nct_id>NCT02851758</nct_id>
  </id_info>
  <brief_title>Transplantation of Autologously Derived Mitochondria Following Ischemia</brief_title>
  <official_title>Transplantation of Autologously Derived Mitochondria for Protection Against Ischemia-reperfusion Injury Following Ischemia in Subjects on ECMO Support</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose a robust therapeutic intervention to ameliorate myocardial&#xD;
      ischemia/ reperfusion injury and significantly decrease morbidity and mortality in patients&#xD;
      requiring extracorporeal membrane oxygenation (ECMO), by direct injection of autogeneic&#xD;
      mitochondria into the ischemic myocardium.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autologous mitochondria will be delivered to the ischemic heart muscle in one of two ways,&#xD;
      during clinically indicated surgical procedure or during clinically indicated cardiac&#xD;
      catheterization.&#xD;
&#xD;
      For surgical re-operation subjects:&#xD;
&#xD;
      After the subject's chest is open, 1-2 6mm biopsies will be collected from the exposed&#xD;
      skeletal muscle of the chest wall. The tissue will be processed at bedside to extract the&#xD;
      autologous mitochondria. Surgery will proceed as clinically indicated. Prior to closure of&#xD;
      the chest, autologous mitochondria will be injected via 5-10 injections of approximately 0.1&#xD;
      mL each to the damaged area (if damaged muscle is local) or via injection into the proximal&#xD;
      aorta while cross-clamped for clinically indicated surgery for global distribution of&#xD;
      mitochondria via the coronary arteries if there is no evident area of damage. Following&#xD;
      completion of surgical maneuvers the mitochondria will be injected into the aorta and the&#xD;
      cross-clamp will be removed. If there is global injury but a cross-clamp is not clinically&#xD;
      indicated, direct injection into the myocardium will occur throughout the ventricle as&#xD;
      previously described. Chest closure will then occur as and if clinically indicated for both&#xD;
      techniques.&#xD;
&#xD;
      For catheterization subjects:&#xD;
&#xD;
      Once in the catheterization lab, the temporary chest closure will be removed and 1-2 6 mm&#xD;
      biopsies will be collected from the exposed skeletal muscle of the chest wall by the cardiac&#xD;
      surgery team. The tissue will be processed at bedside to extract the autologous mitochondria.&#xD;
      The catheterization will proceed as clinically indicated. Prior to completion of the&#xD;
      procedure (interventional to restore blood flow or hemodynamics), mitochondria will be&#xD;
      infused in 5 mL of buffer as conducted in large animal studies (5) via intracoronary infusion&#xD;
      followed by a 5 mL flush with normal saline. Total dose of mitochondria will be equal to&#xD;
      direct injection subjects, with a larger dilution to allow to infusion via cardiac catheter.&#xD;
&#xD;
      If there is no marked improvement in ventricular function following the injection/infusion of&#xD;
      autologous mitochondria and the subject has a clinically indicated procedure in the days&#xD;
      following the initial delivery, a second injection/infusion will be completed. At this time&#xD;
      the follow up schedule will be reset to Day 0.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2, 2017</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety- Incidence of severe adverse events</measure>
    <time_frame>1 week</time_frame>
    <description>Subjects will be SAE free for one week following injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy- Improvement in Outcome measures: increased ventricular function on echocardiogram, measured by ejection fraction</measure>
    <time_frame>1 week- 1 month</time_frame>
    <description>Improvement in ventricular function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy- Improvement in Outcome measures: ability to be separated from ECMO support, measured in days since injection</measure>
    <time_frame>1 week- 1 month</time_frame>
    <description>The ability to decannulate from ECMO support</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Extracorporeal Membrane Oxygenation Complication</condition>
  <arm_group>
    <arm_group_label>Autologous mitochondria injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will have autologous mitochondria injected into ischemic areas of the myocardium (via injection or infusion).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>autologous mitochondria transplantation</intervention_name>
    <description>Autologous mitochondria obtained from the subject's own skeletal muscle will be injected or infused into the ischemic myocardium</description>
    <arm_group_label>Autologous mitochondria injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pediatric cardiology patients under the age of 18 on ECMO&#xD;
&#xD;
          -  concerns for ischemic injury on the Cardiac Intensive Care Unit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known mitochondria disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sitaram M Emani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Breanna Piekarski, RN, BSN</last_name>
    <phone>617-919-4457</phone>
    <email>breanna.piekarski@cardio.chboston.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Breanna Piekarski, RN, BSN</last_name>
      <phone>617-919-4457</phone>
      <email>breanna.piekarski@cardio.chboston.org</email>
    </contact>
    <investigator>
      <last_name>Sitaram M Emani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 25, 2016</study_first_submitted>
  <study_first_submitted_qc>July 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2016</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children's Hospital</investigator_affiliation>
    <investigator_full_name>Sitaram Emani</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

